Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus

Christine A Peschken^{1

2}, Yishu Wang^{3

4}, Michal Abrahamowicz^{3

4}, Janet Pope^{3

4}, Earl Silverman^{3

4}, Amyn Sayani^{3

4}, Sandra Iczkovitz^{3

4}, Jorge Ross^{3

4}, Michel Zummer^{3

4}, Lori Tucker^{3

4}, Christian Pineau^{3

4}, Deborah Levy^{3

4}, Marie Hudson^{3

4}, Carol A Hitchon^{3

4}, Adam M Huber^{3

4}, C Douglas Smith^{3

4}, Antonio Avina-Zubieta^{3

4}, Hector Arbillaga^{3

4}, Gaëlle Chédeville^{3

4}, Willy Wynant^{3

4}, Paul R Fortin^{3

4}; CaNIOS 1000 Faces Investigators

Affiliations

¹ From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA. christine.peschken@umanitoba.ca.
² C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval. christine.peschken@umanitoba.ca.
³ From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
⁴ C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

PMID: 30219771
DOI: 10.3899/jrheum.171454

Multicenter Study

Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus

Christine A Peschken et al. J Rheumatol. 2019 Feb.

. 2019 Feb;46(2):166-175.

doi: 10.3899/jrheum.171454. Epub 2018 Sep 15.

Authors

Affiliations

¹ From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA. christine.peschken@umanitoba.ca.
² C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval. christine.peschken@umanitoba.ca.
³ From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec; University of Western Ontario and St. Joseph's Health Care London, London; Hospital for Sick Children, Toronto; University of Toronto, Toronto; Medical Affairs, GlaxoSmithKline Inc., Mississauga, Ontario; CH Maisonneuve-Rosemont, Montreal; BC Children's Hospital, Vancouver, British Columbia; McGill University Health Centre, Montreal, Quebec; Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, Quebec; IWK Health Centre and Dalhousie University, Halifax, Nova Scotia; University of Ottawa, Ottawa, Ontario; Division of Rheumatology, Arthritis Research Canada, University of British Columbia; Rheumatology Clinic, Calgary, Alberta; Montreal Children's Hospital, McGill University Health Centre, Montreal; Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; GlaxoSmithKline Inc., King of Prussia, Pennsylvania, USA.
⁴ C.A. Peschken, MD, MSc, FRCPC, Departments of Internal Medicine, and Community Health, University of Manitoba; Y. Wang, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; M. Abrahamowicz, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; J. Pope, MD, University of Western Ontario and St. Joseph's Health Care London; E. Silverman, MD, Hospital for Sick Children, and University of Toronto; A. Sayani, PhD, Medical Affairs, GlaxoSmithKline Inc., Mississauga; S. Iczkovitz, BSc, Medical Affairs, GlaxoSmithKline Inc., Mississauga; J. Ross, MD, GlaxoSmithKline Inc., King of Prussia; M. Zummer, MD, CH Maisonneuve-Rosemont; L. Tucker, MD, BC Children's Hospital; C. Pineau, MD, McGill University Health Centre; D. Levy, MD, Hospital for Sick Children, and University of Toronto; M. Hudson, MD, Jewish General Hospital, Lady Davis Institute and McGill University; C.A. Hitchon, MD, MSc, Department of Internal Medicine, University of Manitoba; A.M. Huber, MD, MSc, IWK Health Centre and Dalhousie University; C.D. Smith, MD, University of Ottawa; A. Avina-Zubieta, MD, PhD, Division of Rheumatology, Arthritis Research Canada, University of British Columbia; H. Arbillaga, MD, Rheumatology Clinic, Calgary; G. Chédeville, MD, Montreal Children's Hospital, McGill University Health Centre; W. Wynant, PhD, Department of Epidemiology, Biostatistics and Occupational Health, McGill University; P.R. Fortin, MD, MPH, Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval.

PMID: 30219771
DOI: 10.3899/jrheum.171454

Abstract

Objective: Persistent systemic lupus erythematosus (SLE) disease activity is associated with increased morbidity and mortality. In a multicenter cohort of patients with prevalent SLE, we described persistence, patterns, and predictors of change in disease activity over time.

Methods: Based on SLE Disease Activity Index (SLEDAI)-2K scores at cohort entry, patients were classified into 4 groups: low (score < 4; LOW), moderate (4 to < 6; MOD), moderately high (6 to ≤ 10; MHIGH), and very high (> 10; VHIGH). Multivariable linear and longitudinal mixed linear regression models were used to identify predictors of change over time in SLEDAI-2K.

Results: There were 2019 participants, with declining followup data over 5 years (1326, 580, 274, 186, and 148 patients, respectively). At cohort entry, mean (± SD) age was 42 (± 17) years, disease duration 11 (± 10) years, and 90% were female. The 4 groups included 44% LOW (n = 891), 20% MOD (n = 400), 22% MHIGH (n = 442), and 14% VHIGH (n = 286); therefore, 36% had clinically important SLE activity. The proportion of patients in the LOW group at entry who moved to a higher activity level varied from 30% (167/557) at 1 year, to 49% (41/83) at 3 years, and 54% (30/56) at 5 years. Among 181 patients with MOD to VHIGH entry activity and 3 years of followup, 116 (64.1%) remained active. In all analyses, only higher SLEDAI-2K at cohort entry remained a significant predictor of higher SLEDAI-2K in subsequent years.

Conclusion: Higher SLEDAI-2K at study entry was the single major independent predictor of higher SLEDAI-2K over time, reflecting frequent persistence of active disease, even in patients with longstanding disease. This highlights gaps in the optimal treatment of SLE.

Keywords: DISEASE ACTIVITY; SYSTEMIC LUPUS ERYTHEMATOSUS.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- HighWire
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus

Affiliations

Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical